Today: 30 June 2026
Browse Category

NYSE:INSP 9 December 2025 - 18 December 2025

Inspire Medical Systems (INSP) Stock Plunges on Medicare Coding Reversal: Latest News, Analyst Forecasts, and What Investors Are Watching

Inspire Medical Systems (INSP) Stock Plunges on Medicare Coding Reversal: Latest News, Analyst Forecasts, and What Investors Are Watching

Inspire Medical Systems, Inc. stock tumbled sharply on Thursday, December 18, 2025, after a key Medicare coding tailwind that had fueled recent optimism suddenly looked far less certain. By early afternoon in the U.S. session, INSP was down in the mid-to-high teens, reflecting investor anxiety that a reimbursement “upgrade” tied to a specific billing code may not stick—at least not in the clean, nationwide way many had modeled. MarketBeat
18 December 2025
Inspire Medical Systems (INSP) Stock on December 9, 2025: Rebound Rally Meets Legal Overhang and Mixed Analyst Targets

Inspire Medical Systems (INSP) Stock on December 9, 2025: Rebound Rally Meets Legal Overhang and Mixed Analyst Targets

Inspire Medical Systems, Inc., a leading developer of implantable devices to treat obstructive sleep apnea, is back in the spotlight. As of December 9, 2025, the stock is trading near the upper end of its recent rebound, supported by strong third-quarter results, favorable reimbursement changes, and a series of analyst upgrades—while simultaneously facing a fresh class-action investigation and lingering questions about growth and valuation. investors.inspiresleep.com+1 On December 9, 2025, Inspire Medical Systems shares are changing hands at about $141.72, down slightly on the day after touching an intraday high of $145.01 and a low of $140.58. Trading volume stands around 700,000 shares, reflecting continued investor interest after a volatile year.
9 December 2025
·

Stock Market Today

  • Telix Pharmaceuticals (ASX:TLX) tops Australian growth stocks with large insider holdings
    June 30, 2026, 3:11 AM EDT. Telix Pharmaceuticals (ASX:TLX) is at the front of Australian growth stocks with high insider ownership, seen as a sign of management confidence. The biopharma group, focused on radiopharmaceuticals in cancer imaging and care, pulled in about US$803.8 million in sales, most of that coming from the U.S. The company's market cap stands at A$5.5 billion. Telix's cancer pipeline is broad, and its commercial footing is firm. Its key products, Illuccix and Gozellix, support 2026 revenue targets of US$950-970 million. There's still risk from regulatory and pricing pressure, but insiders remain aligned, and partnerships with United Imaging and Regeneron support the growth story. Also mentioned: Lindian Resources (ASX:LIN), market cap A$1.7 billion, which is pushing ahead on a rare earths project in Malawi. Both names show that shareholder interest tracks with insider backing.
Go toTop